PD-147 A phase I study of a second generation antisenseoligonucleotide to clusterin (OGX-011) in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Preliminary results
Laskin, J., Chi, K., Melosky, B., Sill, K., Hao, D., Canil, C., Gleave, M., Murray, N.Volume:
49
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/s0169-5002(05)80480-5
Date:
July, 2005
File:
PDF, 129 KB
english, 2005